trial

Treating Schizophrenia by Correcting Abnormal Brain Development

NCTId NCT00179465
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Active Not Recruiting
Enrollment 36 (estimated)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2026-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Active Not Recruiting
Enrollment
36 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2003-11
Primary completion
2026-09
Eligibility
ALL · 18 Years · 25 Years

Interventions & indications

Drugs
Tiagabine

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor
Dartmouth-Hitchcock Medical CenterCollaborator

Investigators

1
T.-U. Wilson Woo, M.D., Ph.D.Principal Investigator

Sites

1 total
Boston, United States

Linked catalysts

1
Treating Schizophrenia by Correcting Abnormal Brain Development — primary completion2026-09

Facts & assertions

4 sourced
Enrollment
36
Phase
PHASE3
Primary Completion Date
2026-09
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
Tiagabine
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
collaborator
Dartmouth-Hitchcock Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
T.-U. Wilson Woo, M.D., Ph.D.
person